drugset / Trial / NCT04727580

HSK7653 in Chinese Patients with Impaired Glucose Tolerance

NCT04727580

Phase 2 Completed 99 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.

Timeline

Start
2021-03-29
Primary completion
2022-06-12
Completion
2022-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK7653 Unknown 10 mg Oral
Subject HSK7653 Unknown 25 mg Oral

Indications